Oil Prices Slip as Hormuz Shipping Progress and Rising U.S. Crude Stocks Weigh on Market 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
UK Services PMI Returns to Growth in July as New Orders and Confidence Rebound 
Brazil Cuts Selic Rate to 14% as Inflation Eases but Risks Persist 
Singapore Says One-Third of U.S. Exports Hit by New 12.5% Tariff 
Asian Stocks Mixed as Chip Selloff Hits KOSPI, Nikkei Ahead of US Jobs Data 
Asian Currencies Steady as Markets Await U.S. Jobs Data 
US Stock Futures Hold Steady as Iran Hormuz Deal and Earnings Shape Market Sentiment 
Wall Street Ends Mixed as Dow Hits Record Despite Tech Weakness 
Asian Stocks Slip as AI Rally Fades, Oil Holds Steady on Iran Peace Deal Hopes 
US Stock Futures Rise as Markets Await July Payrolls Data 
Trump Unveils $3 Billion U.S. Critical Minerals Push 
Asian Stocks Cautious Ahead of US Jobs Data as Oil Rises 
Asian Stocks Slide as Semiconductor Selloff Weighs on South Korea and Japan 
BOJ Rate Hike Expectations Rise Ahead of September Meeting 
Australia Trade Surplus Returns in June as Iron Ore, Coal and LNG Exports Surge 
US Dollar Gains as Iran Tensions, Fed Rate Hike Bets Rise 
China has approved Eli Lilly’s Kisunla, marking another milestone in global efforts to address Alzheimer’s disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a unique dosing approach and new hope for managing the disease.
China Approves Kisunla as a New Alzheimer's Treatment Option
After Eisai and Biogen's Leqembi were approved in January, Eli Lilly said late Tuesday that their treatment for early Alzheimer's has been approved by China's medical authorities, giving patients another alternative, Reuters reports.
According to a statement from Lilly, the medication, which is marketed under the trade name Kisunla, has been approved in four key markets: the US, Japan, and the UK. The latest addition to this list is China.
In the same way as Leqembi removes beta-amyloid from the brain, Lilly's Kisunla does the same.
Kisunla Shows Promising Results in Cognitive Decline
Kisunla shown a 29% reduction in the development of cognitive impairments as compared to a placebo in a large, late-stage experiment. Although most occurrences were moderate, it did induce brain edema in approximately 25% of patients and brain bleeding in approximately 33%.
In the United States, the prescribing label for Kisunla bears the FDA's most severe "boxed" safety warning, which, like Leqembi, warns of the possibility of fatal brain enlargement and hemorrhage.
Gradual Dosing and Finite Treatment Benefit Kisunla Users
However, the business reported that the number of patients having potentially significant brain swelling was reduced when Kisunla was started on a more gradual dose schedule.
Another advantage of Kisunla over Leqembi is its finite dosage, which lets patients discontinue treatment once brain scans reveal no more amyloid plaques.
The medicines authority of the European Union is presently evaluating the treatment. In July, the body decided against using Leqembi because the potential for severe brain swelling was not worth the minimal benefit in preventing cognitive loss, Investing.com shares.
Alzheimer’s Drives Majority of Dementia Cases Globally
The World Health Organization reports that between sixty percent and seventy percent of dementia cases are caused by Alzheimer's disease.
